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Phosphoproteomic-based kinase proﬁling early in
inﬂuenza virus infection identiﬁes GRK2 as antiviral
drug target
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Although annual inﬂuenza epidemics affect around 10% of the global population, current
treatment options are limited and development of new antivirals is needed. Here, using
quantitative phosphoproteomics, we reveal the unique phosphoproteome dynamics that
occur in the host cell within minutes of inﬂuenza A virus (IAV) infection. We uncover cellular
kinases required for the observed signaling pattern and ﬁnd that inhibition of selected can-
didates, such as the G protein-coupled receptor kinase 2 (GRK2), leads to decreased IAV
replication. As GRK2 has emerged as drug target in heart disease, we focus on its role in IAV
infection and show that it is required for viral uncoating. Replication of seasonal and pan-
demic IAVs is severely decreased by speciﬁc GRK2 inhibitors in primary human airway
cultures and in mice. Our study reveals the IAV-induced changes to the cellular phospho-
proteome and identiﬁes GRK2 as crucial node of the kinase network that enables IAV
replication.
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Inﬂuenza A viruses (IAV) still pose a substantial burden onhuman health and worldwide economics. Seasonal inﬂuenzaviruses are responsible for up to 500,000 deaths annually, with
immunocompromised individuals at particularly high risk for
severe courses of infection. The appearance and transmission of
pandemic IAV strains, which have caused devastating outbreaks
in the past, additionally threatens global health and urges the
discovery of new antivirals. Cellular factors involved in viral
replication have been proposed to be attractive targets for anti-
viral development1–3. Among them, kinases are particularly
promising, as kinase inhibitors comprise up to 30% of drug-
discovery programs in the pharmaceutical industry3,4.
IAV harnesses the cellular endocytic machinery to enter the
cell and trafﬁc through the cytoplasm to reach the replication
site in the nucleus. Coordinated early activation of signaling
pathways has been shown to be important for viral entry5–13 and
identiﬁcation of key kinases involved in this process could con-
tribute to the development of new antivirals. Binding of IAV
particles, by interaction of the viral hemagglutinin (HA) to
exposed sialylated proteins on epithelial cells14, has been pro-
posed to induce the formation of lipid raft-based signaling plat-
forms, in which receptor tyrosine kinases (RTKs) such as the
epidermal growth factor receptor (EGFR) or c-Met, are acti-
vated6. Clustering of activated RTKs leads to their internalization
in endocytic vesicles, in which the viral particles could be
engulfed15. Downstream of this initial RTK-signaling, early acti-
vation of the phosphatidylinositol-3 kinase (PI3K) has been
shown to promote IAV endocytosis5–7 and, together with the
extracellular signal-regulated kinase ERK1/2, to enhance the
activity of the vacuolar-type H+-ATPases (vATPases)8,16,
which are essential for endosomal acidiﬁcation leading to viral
fusion17–19. Focal adhesion kinase (FAK) has been proposed to
establish a link between this PI3K activation and the cytoskeleton
reorganization required for viral endosomal trafﬁcking9 and the
activation of protein kinase C (PKC) has been shown to play a
role in IAV trafﬁcking through late endosomes10,11. More
recently, Ca2+ signaling has also been implicated in both,
clathrin-dependent and clathrin-independent IAV entry
mechanisms via an intricate associated regulatory network12.
However, a systematic and unbiased analysis of the main sig-
naling routes initiated by IAV binding and key mediators
required for subsequent infection is still lacking. Here we conduct
a SILAC-based quantitative phosphoproteomic analysis of human
lung epithelial cells within minutes post-infection. We quantify
the phosphorylation status of around 3000 different phosphor-
ylation sites from >1300 proteins and identify infection-induced
changes in the phosphorylation pattern. On the basis of this
virus-induced phospho-signature, we are able to identify kinases,
such as the G protein-coupled receptor kinase 2 (GRK2), that are
activated during IAV entry and responsible for the observed
signaling landscape. Inhibition of GRK2 kinase activity severely
decreases IAV uncoating and inhibits viral replication in primary
human airway epithelial cultures, as well as in an animal model of
IAV pathogenesis. Our results therefore establish GRK2 as a
promising drug target for the next generation of antivirals for
inﬂuenza virus.
Results
IAV entry induces a unique phosphorylation signature. In
order to identify cellular kinases required for IAV entry into cells,
we conducted a quantitative phosphoproteomic screen on A549
human lung epithelial cells. We hypothesized that virus binding
to host cells would already induce signaling cascades that enable
the following steps of the replication cycle. As tyrosine phos-
phorylation of epidermal growth factor receptor (EGFR) had
been shown to be induced by HA binding to host cells6, we
monitored EGFR phosphorylation upon infection of A549 cells
with IAV strain A/WSN/33 (MOI= 25 PFU/cell). We observed
strong activation of EGFR at 5 and 15 min post infection (p.i.),
and therefore selected these time points for our analysis (Sup-
plementary Figure 1a). For accurate quantiﬁcation of phosphor-
ylation dynamics, we performed ﬁve biological replicates in A549
cells subjected to triple isotope labeling by amino acids in cell
culture (SILAC)20, from which the peptides phosphorylated at
serine or threonine residues were enriched, and identiﬁed and
quantiﬁed by liquid chromatography coupled to tandem mass
spectrometry (LC-MS/MS) (Fig. 1a). We used IAV A/WSN/33
grown in embryonated chicken eggs for our analysis to avoid
contributions from cytokines, such as interferons, as these act
mostly in a species-speciﬁc manner. In addition, we also per-
formed a proteomic analysis for chicken proteins present in the
virus stock and the allantoic ﬂuid from mock-infected eggs that
we used for our mock condition (Supplementary Data 1). We did
not detect any chicken protein that was at least 2-fold more
abundant compared to the mock, allowing us to attribute dif-
ferences in phosphorylation to virus infection. We were able to
detect >3000 different phosphosites per experimental condition,
from around 2400 phosphopeptides belonging to about 1300
proteins (Supplementary Figure 1b, raw data in Supplementary
Data 2). As expected, the vast majority of the detected phos-
phosites were phospho-serine and -threonine modiﬁcations, and
only few phospho-tyrosines. A total of 70% of the phosphosites
were detected in more than one biological replicate with a good
correlation between them (Supplementary Figure 1c, d). Quan-
titative analysis performed using MaxQuant21 revealed changes in
phosphorylation of an important subset of phosphopeptides
within minutes of virus addition, while the absolute peptide
abundance, quantiﬁed from total extract digests, remained mostly
unaltered. Using a cutoff value of 1.5-fold change (FC) compared
to mock infected samples, 213 phosphosites were found to be
differentially phosphorylated 5 min post-inoculation (Fig. 1b),
133 of which were dephosphorylated and 80 showing an increase
in phosphorylation. 15 min after the addition of virus, changes in
phosphorylation were more pronounced, with 375 sites being
differentially phosphorylated (Fig. 1c), 257 dephosphorylated and
118 showing an increase in phosphorylation. These data reveal
that different cellular signaling pathways are activated within
minutes of IAV infection, possibly induced by virus binding to
the cell surface.
To determine which cellular functions are regulated by
phosphorylation early in IAV infection, we analyzed the cellular
pathways to which the proteins containing IAV-responsive
phosphosites are assigned. The distributions of annotated KEGG
(Kyoto Encyclopaedia of Genes and Genomes) pathways22 among
differentially phosphorylated proteins (log2FC ≥ 0.5, at either 5 or
15min post-infection) were compared against the background of
the total population of identiﬁed phosphorylated proteins (Fig. 1d
and Supplementary Table 1). Proteins with a described function in
MAPK signaling (adj. p value= 2.29e−08 (hypergeometric test)),
endocytosis (adj. p value= 1.13e−06 (hypergeometric test)) and
regulation of the actin cytoskeleton (adj. p value= 5.79e−06 (hyper-
geometric test)) were overrepresented among the proteins phos-
phorylated in response to infection. As these cellular functions are
known to be required for IAV entry, this result validates our
experimental approach5–8,16,23–26. Furthermore, proteins related to
focal adhesions and tight junctions (adj. p value= 6.47e−03 (hyper-
geometric test)), thus far not described to be involved in the early
stages of IAV infection, were found to be signiﬁcantly enriched.
Among them, integrins (ITGB4), actin-binding proteins such as
parvins (PARVA) and ﬁlamins (FLNB), proteins related to actin-
membrane attachment (PXN, EPB41L1, VAPA) and different
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cytoskeleton components (TLN1), which were not previously
associated with viral entry, were phosphorylated within minutes
of infection. We also generated a network to analyze how the
differentially phosphorylated proteins are interconnected within the
different pathways and identiﬁed a clear cross-talk between them
(Fig. 1e).
Kinase proﬁling reveals IAV-responsive kinases. As our main
goal was to reveal novel drug targets for IAV, we next focused on
the kinases activated in response to infection. To this aim, we
developed a bioinformatics pipeline to identify cellular kinases
that could be responsible for the phosphorylation of the IAV-
responsive phosphosites in our data set. Our approach centres on
the kinase predictions obtained from the Group-based Prediction
System 3.0 (GPS 3.0)27–29 including a redeﬁned high stringency
cutoff (see Methods and Supplementary Figure 2). GPS 3.0 ranks
the likelihood that a particular kinase or kinase family
phosphorylates a given residue considering the amino acids sur-
rounding the phosphorylation site. Putative kinases for the
hyperphosphorylated sites at both 5 and 15 min post-infection
(log2FC ≥ 0.5) were identiﬁed and the distribution of the top
predicted IAV-responsive kinases was compared against the
background of the kinases predicted for the total population of
identiﬁed phosphopeptides (Fig. 2a). Putative substrates for
mitogen-activated protein kinase 1 (MAP2K1/MEK1), MAP
kinase-interacting serine/threonine-protein kinase 2 (MNK2,
p value= 0.043 (Fisher's exact test)) and RP6KB1 (p value=
0.023 (Fisher's exact test)) were the top hits among the hyper-
phosphorylated peptides 5 min after IAV binding. Predicted
substrates for cyclin-dependent kinase 1 (CDK1), CDK5 and
polo-like kinase 2 (PLK2, p value= 0.003 (Fisher's exact test)) are
signiﬁcantly phosphorylated 15 min after the addition of the
virus. Interestingly, G protein-coupled receptor kinase 2 (GRK2),
p21 (RAC1) activated kinase 1 (PAK1), Rho-associated coiled-
ca
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Fig. 1 IAV-induced changes in the host cell phosphoproteome. a Overview of the experimental design. b, c Distribution of changes in cellular
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coil containing protein kinase 1 (ROCK1, p value= 0.003 (Fish-
er's exact test)) and unc-51 like kinase 3 (ULK3, p value=
0.002 (Fisher's exact test)) are predicted to be activated at both
time-points analyzed. Some of these kinases, like MAPKs or
MNKs (MAPK/ERK signaling)7,8,16, ROCK112,23, or PAK113,30,
have already been implicated in viral entry, and thus validate our
analysis. However, we also revealed CDKs, GRK2 and ULK3 as
novel kinases activated in early steps of IAV replication. Next, the
amino acids adjacent to the hyperphosphorylated positions at 5
and at 15 min post-infection (log2FC ≥ 0.5) were analyzed to
identify conserved sequences that could be linked to the recog-
nition motifs for the predicted kinases. We identiﬁed four
sequences enriched among the IAV-responsive phosphopeptides
(Fig. 2b). A proline (P) in position +1 is particularly over-
represented (39%) among the putative targets for CDKs and
MAPK. In agreement with these results, this motif is part of the
optimal recognition sequences proposed for CDKs and for ERK
and MAPK families31, whose activation has been shown to be
required for IAV entry6–8,16. An arginine (R) in position −3 is
also enriched among the IAV-responsive phosphopeptides (18%),
especially among putative targets for PAK1, ROCK1 and
RP6KB1. This particular feature is part of the optimal recognition
sequence predicted for PKCs, PKA or ROCK131, and these
kinases have been linked to IAV entry into cells10–12,23. Finally,
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a glutamic acid (E) in position +3 (22%) or a serine (S) in
position +2 (16%) are likewise associated with IAV-responsive
phosphosites among putative targets of PLK2, RP6KB1 or GRK2
in our analysis.
Inhibition of GRK2 potently inhibits IAV replication. Next, we
evaluated whether viral replication could be reduced by tar-
geting the in silico-identiﬁed IAV-responsive kinases with
small molecular weight compound inhibitors (Fig. 2c). We
tested the effect of speciﬁc PAK1 (IPA-3), ROCK1 (Y-27632)
and GRK2 (Methyl 5-[2-(5-nitro-2-furyl)vinyl]-2-furoate,
GRK2i)32 inhibitors on the replication of a luciferase-encoding
reporter IAV. Together with ULK3, these are the kinases pre-
dicted to be activated by IAV at both time-points that were
analyzed (Fig. 2a). As inhibitors for ULK3 are not commer-
cially available, ULK3 was excluded from the analysis. We also
included a CDK inhibitor (AT7519)33 because CDKs are key
cellular kinases that have not been linked to early steps of IAV
infection. Given that the MAPK pathway has been broadly
implicated in viral entry6–8,16 and is among the top hits in our
pathway enrichment analysis (Fig. 1d), a speciﬁc ERK inhibitor
(Ulixertinib)34 was also included as positive control. Cyto-
toxicity of the different compounds in A549 cells was deter-
mined (Supplementary Figure 3a) and concentrations without
deleterious effects were used for further experiments. As
expected, the ERK inhibitor efﬁciently blocked virus replica-
tion in a dose-dependent manner (Fig. 2c). PAK1 inhibition
partially reduced viral replication, which is consistent
with a previous report on the role of PAK1 in IAV infection13.
We could not observe a signiﬁcant effect upon ROCK1 tar-
geting in our experimental system but both the CDK and
GRK2 inhibitors efﬁciently blocked viral replication, conﬁrm-
ing the prediction of our kinase activation proﬁling (Fig. 2c).
In these cases, the inhibition of viral replication was
clearly observed at 4 h post-infection (hpi), suggesting that, as
predicted by our phosphoproteomic data, both CDKs and
GRK2 are required for an early step in the viral replication
cycle.
In order to further explore the possibility of targeting GRK2 to
inhibit IAV, we ﬁrst assessed the impact of GRK2 depletion on
viral growth. A549 cells were transfected with four different
small interfering RNAs (siRNAs) targeting GRK2, a scrambled
siRNA (siSCR) control or an siRNA targeting a vATPase
required for endosomal acidiﬁcation during viral entry. First,
silencing efﬁciency (Supplementary Figure 3b) and impact on
cell viability (Supplementary Figure 3c) of the different siRNAs
were analyzed. All four siRNAs reduced GRK2 expression to
comparable levels but had only minor effects on cell viability. At
48 h post-siRNA transfection, cells were infected with IAV (A/
WSN/33) at a low multiplicity of infection (MOI= 0.001 PFU/
cell) and supernatants were harvested 24 h and 48 h later
(Fig. 3a). Each of the siRNAs reduced viral titers by 10–100-
fold, further supporting the role of GRK2 as a host factor
required for IAV infection. Next, we performed similar
experiments in siRNA-treated A549 cells using the human IAV
strain A/Udorn/72 (H3N2) (Fig. 3b) or the highly pathogenic
avian strain A/FPV/Dobson/34 (H7N7) (Fig. 3c). GRK2 deple-
tion also inhibited replication of these viruses. Finally, to discard
a cell-line-speciﬁc requirement, we also transfected siRNAs
targeting GRK2 and the above described controls into MRC5 or
Wi38 human lung ﬁbroblasts, which were subsequently infected
with A/WSN/33 (Supplementary Figure 3d, e). Although the
virus was not able to replicate as efﬁciently as in A549 cells,
depletion of GRK2 signiﬁcantly impaired viral replication in
both cell lines.
IAV induces activation of GRK2. As GRK2 was one of the top
hits predicted to be responsible for the observed IAV-induced
phosphorylation signature, we hypothesized that GRK2 was
activated by IAV. Previous reports showed that differential
phosphorylation regulates GRK2 activity35–38 and we thus
speculated that the phosphorylation status of GRK2 would
change in response to IAV infection. However, we had not
detected phosphopeptides derived from GRK2 in our proteomic
analysis, possibly suggesting activation of GRK2 by tyrosine
phosphorylation. In order to assess the phosphorylation status of
GRK2 in response to IAV we employed phosphate afﬁnity
polyacrylamide gel electrophoresis39. This method makes use of a
compound that binds to phosphate groups and thereby speciﬁ-
cally slows the migration of phosphorylated proteins during gel
electrophoresis, which enables visualization of differentially
phosphorylated forms of a given protein. As EGF had been
reported to induce tyrosine phosphorylation of GRK2, we vali-
dated the method by transfecting A549 cells with constructs
encoding GRK2 and EGFR, treated cells with epidermal growth
factor (EGF) for 5 or 15 min and performed phosphate afﬁnity
polyacrylamide gel electrophoresis35. As control, we treated the
lysates with lambda protein phosphatase (LPP). When cells were
stimulated with EGF, we observed a stronger signal for the
phosphorylated version of GRK2, which was not present when
the samples had been treated with LPP (Fig. 3d). Importantly, we
also observed the appearance of the phosphorylated form of
GRK2 upon IAV infection (Fig. 3e) conﬁrming our hypothesis
that GRK2 is phosphorylated within minutes of infection.
As activation of kinases often leads to their translocation, we
also analyzed GRK2 localization in response to IAV infection. We
again used EGF treatment as positive control as it had been
shown that GRK2 translocates to EGFR-positive clusters at the
plasma membrane upon EGFR stimulation35. Interestingly, we
found that IAV infection also induced the translocation of GRK2
to plasma membrane clusters, where it colocalized with EGFR
(Fig. 3f; Supplementary Figure 3f). The translocation of GRK2
was also observed when using a puriﬁed stock of IAV
(Supplementary Figure 3g), allowing us to attribute GRK2
activation to viral particles and ruling out contributions from
other allantoic ﬂuid components. Of note, the IAV-induced
GRK2 translocation was dependent on EGFR, as we could not
observe it in cells lacking EGFR expression (Fig. 3g). Thus, we
conclude that IAV infection induces GRK2 phosphorylation and
translocation to EGFR-positive membrane clusters.
GRK2 kinase activity is required for IAV uncoating. From our
results thus far, we hypothesized that the kinase activity of GRK2
is required for early steps of the viral replication cycle. To verify
this, we performed a time of addition experiment in which the
GRK2 inhibitor (GRK2i) was added to cells at different times
post-infection (Fig. 4a). Addition of the compound together with
the virus inoculum efﬁciently reduced the replication of a Renilla
luciferase-encoding reporter IAV. Adding the inhibitor at 2 or 4
hpi reduced viral replication less efﬁciently, while addition of the
inhibitor at later time points did not affect the progression of the
infection. Furthermore, addition of the compound only during
virus binding or during the ﬁrst 1–3 h of infection, followed by a
washing step and the replacement by inhibitor-free medium, was
sufﬁcient to block the replication of the reporter virus (Fig. 4b).
To further verify these observations, we performed a similar
experiment, using the IAV A/WSN/33 strain, in which super-
natants from inhibitor-treated and infected A549 cells were col-
lected 12 hpi and virus titers were determined by plaque assay
(Fig. 4c). Addition of the inhibitor during the ﬁrst 3 h of infection
was sufﬁcient to reduce viral production by more than 1000-fold,
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conﬁrming the requirement for GRK2 activity during the early
steps of the viral cycle. Next, we evaluated the amount of viral
nucleoprotein (NP) within the cell nucleus 3 hpi as a direct
measurement of the early infection progression. A549 cells were
pre-treated for 1 h with GRK2i, subsequently infected with A/
WSN/33 at a high multiplicity of infection (MOI= 5 PFU/cell)
for 3 h in the presence of the inhibitor and analyzed by confocal
microscopy (Fig. 4d). In control-treated cells, NP was clearly
detected in the nucleus as a consequence of ongoing viral repli-
cation. However, both GRK2i and BafA1, which was used as
positive control, efﬁciently blocked nuclear NP accumulation.
Similar results were obtained in A549 cells transfected with siR-
NAs targeting GRK2 (Supplementary Figure 4a). When transla-
tion was blocked in a similar experimental setup by addition of
f DAPI DAPI
M
oc
k
M
oc
k
5 
m
in
15
 m
in
30
 m
in
EG
F
A/
W
SN
/1
93
3
HA-GRK2 HA-GRK2Myc-EGFR Myc-EGFROverlay OverlayZoom g
*
*
*
**
**
*
*
*
*
**
*
*
*
*
*
*
*
*
*
*
*
*
a b c
Vi
ru
s 
tit
er
 (P
FU
/m
l)
108
100
101
102
103
104
105
106
107
108
100
101
102
103
104
105
106
107
100
101
102
103
104
105
106
107
A/WSN/33 (H1N1)
si
SC
R
si
vA
TP
as
e
si
G
RK
2#
1
si
G
RK
2#
2
si
G
RK
2#
9
si
G
RK
2#
10
si
SC
R
si
vA
TP
as
e
si
G
RK
2#
1
si
G
RK
2#
2
si
SC
R
si
vA
TP
as
e
si
G
RK
2#
1
si
G
RK
2#
2
si
SC
R
si
vA
TP
as
e
si
G
RK
2#
1
si
G
RK
2#
2
si
SC
R
si
vA
TP
as
e
si
G
RK
2#
1
si
G
RK
2#
2
si
SC
R
si
vA
TP
as
e
si
G
RK
2#
1
si
G
RK
2#
2
si
G
RK
2#
9
si
G
RK
2#
10
24 hpi 48 hpi 24 hpi 48 hpi
Vi
ru
s 
tit
er
 (P
FU
/m
l)
A/Udorn/72 (H3N2)
Vi
ru
s 
tit
er
 (P
FU
/m
l)
A/FPV/Dobson/34 (H7N7)
16 hpi 24 hpi
e
Mock 5 min 15 min 120 min 180 min
A/WSN/33 (H1N1)
GRK2
pGRK2
Actin
70
100
40
kDa
d
Mock 5 min 15 min Mock 5 min 15 min
GRK2
pGRK2
Actin
70
100
40
kDa
EGF–LPP EGF+LPP
Fig. 3 GRK2 is a proviral host factor that becomes activated within minutes of IAV infection. a–c Effect of GRK2 silencing on the replication of A/WSN/33
(H1N1) (a), A/Udorn/72 (H3N2) (b) or A/FPV/Dobson/34 (H7N7) (c) in A549 cells. At 48 h post siRNA transfection, cells were infected with IAV,
supernatants were collected at the indicated times and virus titers were determined by plaque assay. Error bars represent standard deviation from three
independent experiments, each performed in triplicates. Statistical signiﬁcance was determined by unpaired t-test. For all panels, ns (non-signiﬁcant)= P >
0.05; *P≤ 0.05; **P≤ 0.01. d A549 cells were transfected with HA-GRK2 and myc-EGFR-encoding plasmids, serum starved for 16 h before being
stimulated with recombinant human epidermal growth factor (hrEGF 100 ng/ml). The phosphorylation status of the indicated proteins was examined using
a Zn2+ Phos-tag gel. Samples on the right (+LPP) were treated with lambda protein phosphatase (LPP) for 30min at 30 °C before being run on a Zn2+
Phos-tag gel. e Same experimental set up as in panel (d), but cells were infected with A/WSN/1933 with an MOI= 100 PFU/cell. f Hep-2 cells were
transfected with HA-GRK2- and myc-EGFR-encoding plasmids and 24 h later stimulated with hrEGF or infected with A/WSN/1933 (MOI= 100 PFU/cell)
for 15 min. Cells were ﬁxed and stained using antibodies against the HA-tag (green), EGFR (red) and DAPI (blue) to mark the nuclei. Scale bar corresponds
to 10 μm, for zoom images scale bar corresponds to 2.5 μm. g Hep-2 cells were transfected with an HA-GRK2-encoding plasmid and 24 h later infected
with A/WSN/1933 (MOI= 100 PFU/cell) for 5, 15 or 30min. Cells were ﬁxed and stained as in (f). Scale bar corresponds to 10 μm
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06119-y
6 NATURE COMMUNICATIONS |  (2018) 9:3679 | DOI: 10.1038/s41467-018-06119-y | www.nature.com/naturecommunications
cycloheximide in order to detect only incoming viral ribonu-
cleoproteins (vRNPs), the nuclear accumulation of NP was
severely impaired in the presence of GRK2i (Fig. 4e), suggesting
that the activity of the kinase is required before or during the
nuclear import of parental vRNPs.
We then tested whether GRK2 was required for virus
internalization or endosomal trafﬁcking. A549 cells were pre-
treated for 1 h with GRK2i or equivalent amounts of the solvent
dimethyl sulfoxide (DMSO), prior to infection with A/WSN/33 for
30min at an MOI= 25 PFU/cell. To quantify the amount of
virions in early endosomes, we performed confocal immunoﬂuor-
escence analysis of NP and the early endosome antigen 1 (EEA1)
and measured the percentage of co-localization using Imaris
software40,41. No signiﬁcant differences in co-localization of
internalized virions with EEA1 were observed in cells treated with
the inhibitor (Supplementary Figure 4b), suggesting that GRK2 is
not required for binding, internalization or early endosomal
trafﬁcking. Next, we characterized whether GRK2 function was
necessary for efﬁcient viral fusion. To do this, we generated IAV
virus-like particles (VLPs) that contain HA and NA from the
A/WSN/33 strain and harbor a beta-lactamase reporter protein
fused to the inﬂuenza matrix protein-1 (BlaM1)42. Upon fusion of
viral and endosomal membranes, BlaM1 gains access to the
cytoplasm, where it cleaves the ﬂuorogenic substrate CCF-2, which
then shifts to a shorter ﬂuorescent emission wavelength that can be
detected by ﬂow cytometry. Although GRK2 impairment can
efﬁciently block nuclear accumulation of NP in MDCK cells 3 hpi
at non-toxic concentrations of GRKi (Supplementary Figure 4c, d),
no differences in viral fusion were detected in the presence of the
inhibitor (Supplementary Figure 4e).
Next, we evaluated whether GRK2 is required for the uncoating
process, in which the M1 protein core dissociates from the
vRNPs, allowing their release into the cytosol of the infected cells.
A549 cells were infected with A/WSN/33 at an MOI= 25 PFU/
cell for 3 h in the presence of the inhibitor or equivalent
amounts of the solvent DMSO. To determine the efﬁciency of
the uncoating process, we performed confocal immunoﬂuores-
cence analysis with an M1-speciﬁc antibody, which targets an
epitope that is solely accessible after uncoating43, and quantiﬁed
the intensity of the staining using ImageJ. In DMSO-treated cells,
as a consequence of the uncoating of the virions, the M1 epitope
recognized by the antibody is exposed and a green staining was
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observed across the cytoplasm. However, upon BafA1 treatment
or GRK2 inhibition, the intensity of the staining was signiﬁcantly
reduced and conﬁned to discrete structures in the cytoplasm
(Fig. 4f). Altogether, these results map the requirement of GRK2
to the viral uncoating process.
Given the role of the viral M1, M2 and NP proteins in
uncoating, we also analyzed the phosphorylation status of these
proteins in the absence or presence of a GRK2 inhibitor. We did
not observe phosphorylation of M1 or NP, but we found that M2
was phosphorylated (Supplementary Figure 5), which is in line
with published results on the phosphorylation status of M2 in
virus particles44. However, no difference was observed between
inhibitor-treated and untreated samples (Supplementary Figure 5)
suggesting that GRK2 exerts its proviral function via a cellular
rather than a viral target.
GRK2 inhibition limits IAV in human airway cultures and
mice. Next, we tested the antiviral activity of paroxetine, a
selective serotonin reuptake inhibitor (SSRI) recently shown to
also inhibit GRK2 activity in vitro, in cell culture and in mice45,46
(Fig. 5a). Paroxetine efﬁciently blocked IAV replication in a dose-
dependent manner, being slightly more efﬁcient than the GRK2
inhibitor used in our previous experiments. The control SSRI
ﬂuoxetine did not inhibit IAV infection (Supplementary Fig-
ure 6a) suggesting that paroxetine inhibited IAV via GRK2
inhibition rather than its function as SSRI. While A549, MRC5
and Wi38 are widely used models for IAV infection, they do not
represent the complexity of the human airway epithelia. We
therefore evaluated the antiviral activity of both GRK2 inhibitors
in primary human bronchial epithelial cells differentiated into
pseudostratiﬁed human airway epithelial (HAE) cultures under
“air-liquid-interface” (ALI) conditions47. Fully differentiated
HAE cultures from different donors were pre-treated with inhi-
bitors for 1 h and subsequently infected with human IAV strains
A/Netherlands/602/2009 (pdmH1N1), A/Brisbane/59/07 (H1N1),
A/HongKong/68 (H3N2) or A/Brisbane/10/07 (H3N2) for 4 h in
the presence of the inhibitors (Fig. 5b). Both compounds blocked
nuclear accumulation of NP efﬁciently for all virus strains, with
paroxetine being more potent. We then infected HAE cultures
with the different strains of IAV and collected supernatants 16
and 24 hpi to quantify virus production by plaque assay
(Fig. 5c–f). Paroxetine reduced virus titers by 100 to 1000-fold for
all strains tested, conﬁrming that blocking GRK2 activity could be
used to limit IAV infection in human lung epithelia. Finally, we
tested whether chemical inhibition of GRK2 could reduce viral
replication and severity of infection in mice. As no data were
available for the stability and bioavailability of GRKi in vivo, we
selected paroxetine, which had been used in mice before, for our
experiments46. 9 week old C57BL/6 J mice were injected intra-
peritoneally (i.p.) with 5 mg/kg paroxetine or an equivalent
amount of solvent. At 24 h post treatment, mice were challenged
with 10 PFU of a mouse-adapted A/Netherlands/602/2009
(pdmH1N1) or inoculated with phosphate-buffered saline (PBS)
via the intranasal route. Paroxetine or solvent treatment was
repeated on the day of infection and on days 1 (d1) and d2 post
infection (pi). For one group of mice, weight loss and survival
were monitored but no signiﬁcant changes were observed
between the paroxetine-treated group and the solvent control
group (Supplementary Figure 6b, c). For a second group of mice,
virus titers on d2 and d4 pi were determined from snout and lung
homogenates to track the progression of the infection in the
upper (URT) and lower respiratory tract (LRT) (Fig. 5g, h). No
signiﬁcant differences were observed in virus titers from d2 pi.
However, paroxetine treatment decreased virus titers signiﬁcantly
in both organs on d4 pi. In summary, our results show that
inhibition of GRK2 led to strongly reduced viral titers in primary
human airway cultures and also limited viral replication in a
mouse model. However, GRK2 inhibition could not protect mice
from weight loss or death in a lethal challenge model. While
further in vivo studies using more potent GRK2 inhibitors will be
needed to fully assess the potential of GRK2 inhibition as ther-
apeutic option, our results establish GRK2 as novel drug target
candidate for inﬂuenza.
Discussion
Binding of IAV to its host cell triggers complex signaling cascades
that regulate internalization of the virus but can also impact later
events in the infection cycle. In order to obtain a global picture of
the virus-induced signaling events in an unbiased manner, we
applied quantitative phosphoproteomics to cells infected with
inﬂuenza viruses for 5 or 15 min and revealed the unique IAV-
induced phosphorylation signature. Even though our approach
was limited to the identiﬁcation of phospho-serine and -threonine
containing peptides and did not include phospho-tyrosines, we
uncovered >200 infection-induced changes in the phosphoryla-
tion status of cellular proteins within minutes of virus addition.
We found that the MAPK pathway was the most prominent
signaling cascade induced. While it was known before that this
pathway becomes activated in response to IAV6,48, our study
reveals its central role in early stages of inﬂuenza virus infection.
As our main goal was to uncover novel drug targets for
inﬂuenza, we focused on the identiﬁcation of kinases that could
be responsible for the observed changes in phosphorylation. A
similar analysis for phosphatases would be equally interesting but
thus far, bioinformatic tools for phosphatase prediction are less
well developed. We found GRK2, ULK3, ROCK1 and PAK1
predicted to be involved in phosphorylation events identiﬁed at
both time points analyzed. While a role for ROCK1 and PAK1 in
IAV entry has been proposed before12,13,30, GRK2 and ULK3
have not been implicated in inﬂuenza virus infections yet. ULK3
can interact with the ESCRTIII complex and functions in cyto-
kinetic abscission. Speciﬁcally, ULK3 is required for delaying cell
division if the chromosomes have not segregated yet49. With
regard to viruses, ULK3 was found to be upregulated in cyto-
megalovirus infection but the functional relevance of this obser-
vation is unclear50. To our knowledge, no speciﬁc inhibitors of
ULK3 have been developed yet and thus, the suitability of ULK3
as potential drug target for inﬂuenza is currently limited. In
contrast, GRK2 is the target of intense research efforts. This
kinase is best known for its role in G-protein-coupled receptor
(GPCR) signaling, where GRK2 is recruited to the receptor upon
activation, phosphorylates the GPCR, which in turn leads to
binding of beta-arrestin to the receptor. This impairs
downstream signaling and thereby leads to rapid desensitization.
Furthermore, beta-arrestin binding also triggers receptor inter-
nalization and subsequent lysosomal degradation51. Increased
levels of GRK2 are therefore associated with a reduction in GPCR
signaling and this is particularly well documented for beta-
adrenergic receptor signaling in heart tissue, where increased
levels of GRK2 are linked with impaired cardiac contractility51,52.
Hence, GRK2 has emerged as promising drug target in heart
disease and inhibitor development is under way53,54, which could
eventually enable drug repurposing for the treatment of inﬂuenza
virus infections.
At this point, the target(s) of GRK2 through which the kinase
exerts its proviral function for IAV are not known. As described
above, beta-arrestin is the best-studied substrate of GRK2 but we
did not detect any phosphopeptides derived from beta-arrestin in
our proteomic analysis. Furthermore, data from a meta-analysis
of several genome-wide RNAi screens for required host factors of
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IAV48 suggest that beta-arrestin is not a required host factor for
IAV, and therefore most likely does not mediate the proviral
function of GRK2. Of note, GRK2 was recently described as key
stimulator of histone deacetylase 6 (HDAC6)36, which in turn has
been proposed to be recruited to viral fusion sites and enable
efﬁcient uncoating in a complex mechanism involving the
aggresome processing machinery43. However, GRK2-mediated
phosphorylation of HDAC6 has been shown to stimulate its
α-tubulin deacetylase activity, which is not required for viral
uncoating. In addition, no HDAC6-derived phosphopeptide was
detected in our analysis suggesting that GRK2 does not exert its
proviral role through HDAC6. As we also did not observe any
changes in the phosphorylation status of the viral proteins M1,
M2 and NP in the presence of a GRK2 inhibitor, we speculate
that GRK2 supports the viral uncoating process by phosphor-
ylating non-canonical cellular targets. Further characterization of
the interplay between GRK2, the components of the aggresome
system and the cellular cytoskeleton will help to reveal the
molecular mechanism of IAV uncoating.
Interestingly, GRK2 was recently shown to promote both, entry
and RNA synthesis, of yellow fever virus (YFV), dengue virus
(DENV) and Hepatitis C virus (HCV)55, which are ﬂaviviruses
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Fig. 5 IAV replication can be limited by the use of GRK2 inhibitors in human airway cultures and in mice. a A549 cells were treated for 1 h with the
indicated amounts of the different compounds and infected on ice with IAV A/WSN/33 (H1N1) at an MOI= 5 PFU/cell. Cells were incubated at 37 °C for
3 h in presence of the inhibitors, ﬁxed and stained for viral nucleoprotein (NP, green) and nuclei (blue). The distribution of NP at the different time-points
was analyzed by confocal microscopy and mean ﬂuorescence intensity (MFI) in the cell nuclei (n > 200) was quantiﬁed using ImageJ. One representative
out of four independent experiments is shown. Statistical signiﬁcance was determined by unpaired t-test. b Fully differentiated human airway epithelial
(HAE) cultures were infected with the indicated human IAV strains (107 PFU/well) in presence of the indicated compounds. Cells were processed and NP
nuclear staining was quantiﬁed as described in (a). Scale bar corresponds to 40 µm. One representative out of at least two independent experiments is
shown. c–f HAE cultures were infected with the indicated human IAV strains (1000 PFU/well) in presence or absence of paroxetine. At the indicated times
post-infection, supernatants were harvested and virus titers were determined by plaque assay. For a–f, error bars represent standard deviation and
statistical signiﬁcance was determined by unpaired t-test. g, h Virus titers in the upper respiratory tract (URT) and lower respiratory tract (LRT) of mice
treated with solvent (gray) or paroxetine (red) and infected with A/Netherlands/602/2009 (pdmH1N1) for 2 and 4 d pi are depicted (two independent
experiments, n≥ 8 per group). Statistical signiﬁcance was determined using non-parametric two-tailed Mann–Whitney test. For all panels, ns (non-
signiﬁcant)= P > 0.05; *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001; ****P≤ 0.0001
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causing severe disease in humans. Together with our ﬁndings that
GRK2 is a key kinase involved in the initial steps of IAV infection,
this suggests that inhibition of GRK2 function may represent a
promising opportunity for the development of broad spectrum
antivirals. In summary, our work reveals the unique phosphor-
ylation signature induced by IAV within minutes of infection and
identiﬁes GRK2 as lead target for host cell-directed antivirals.
Methods
Chemicals and reagents. The following compounds were used: dimethyl sulfoxide
(DMSO, Sigma-Aldrich), baﬁlomycin A1 (Sigma-Aldrich), AT7519 (CDK inhi-
bitor, Selleckchem), ulixertinib (MAPK inhibitor, Selleckchem), IPA-3 (PAK1
inhibitor, Selleckchem), Y-27632 (ROCK1 inhibitor, Selleckchem), methyl 5-[2-(5-
nitro-2-furyl)vinyl]-2-furoate (GRK2 inhibitor, Santa Cruz Biotechnology), cyclo-
heximide (Sigma-Aldrich) and paroxetine (GRK2 inhibitor, Sigma-Aldrich). For
western blotting and immunoﬂuorescence, the following primary antibodies were
used: rabbit polyclonal anti-GRK2 antibody (C-15, Santa Cruz Biotechnology, sc-
562, western blot 1:1000 dilution), mouse monoclonal anti-β-actin antibody (C4,
Santa Cruz Biotechnology, sc-47778, western blot 1:1000 dilution), rabbit poly-
clonal anti-hEGFR (1005, Santa Cruz Biotechnology, sc-03-G, immunoﬂuorescence
1:100 dilution, western blot 1:1000 dilution), mouse monoclonal anti HA-Tag (Cell
Signaling #2367, immunoﬂuorescence 1:100 dilution), rabbit polyclonal anti-NP
antibody for western blotting (kind gift of A. Nieto, Centro Nacional de Bio-
tecnología, Madrid, Spain, western blot 1:1000 dilution), rabbit polyclonal anti-NP
antibody for immunoﬂuorescence (kind gift of P. Palese, Mount Sinai Hospital,
NY, USA, immunoﬂuorescence 1:2000 dilution), mouse monoclonal anti-NP
(ATCC HB65, H16-L10-4R5, immunoﬂuorescence 1:5 dilution), mouse mono-
clonal anti-M1 antibody (ATCC HB64, M2-1C6-4R3, immunoﬂuorescence 1:5,
western blot 1:5 dilution), rabbit polyclonal anti-IAV M2 (ThermoFisher, PA5-
32233, western blot 1:1000 dilution) and mouse monoclonal anti-EEA1 antibody
(BD Bioscience, #610457, immunoﬂuorescence 1:2000).
Cells and viruses. A549 (CCL-185), MRC5 (CCL-171) and Wi38 (CCL-75) were
obtained from ATCC. Hep-2 were a kind gift of J. Pavlovic, Institute of Medical
Virology, Zurich, Switzerland and MDCK were kindly provided by Ben Hale,
Institute of Medical Virology, Zurich, Switzerland. A549, Hep-2 and MDCK cells
were maintained in Dulbecco’s modiﬁed Eagle medium (DMEM) supplemented
with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin and streptomycin
(Life Technologies). MRC5 and Wi38 were maintained in minimal essential Eagle
medium (MEM, Sigma-Aldrich) supplemented with 10% (v/v) fetal bovine serum
(FBS) and 1% (v/v) penicillin and streptomycin (Life Technologies). Isolation and
cultivation of primary human bronchial epithelial cells to form pseudostratiﬁed/
differentiated human airway epithelial (HAE) cultures was performed as described
previously56,57. Inﬂuenza virus strains A/WSN/1933 (H1N1), A/Udorn/72 (H3N2),
A/Netherlands/602/2009 (pdmH1N1), A/Brisbane/59/07 (H1N1), A/HongKong/
68 (H3N2) or A/Brisbane/10/07 (H3N2) were kindly provided by P. Palese, Mount
Sinai Hospital, NY, USA. Strain A/FPV/Dobson/34 (H7N7) was a kind gift of J.
Pavlovic, Institute of Medical Virology, Zurich, Switzerland. All virus stocks were
grown in 10-day old embryonated chicken eggs and titered by plaque assay on
MDCK cells.
Virus infection and titration. For virus infection, cells were washed once with PBS
supplemented with 20 μM Mg2+, 10 μM Ca2+, 0.3% (w/v) bovine serum albumin
(BSA), and 1 % (v/v) penicillin-streptomycin (infection PBS). In case of HAE
cultures, three washes with infection PBS were performed. MOI-adjusted inoculum
was subsequently added to the cells, which were incubated for 1 h at room tem-
perature (RT) or for 1 h on ice, in case infection synchronization was needed. After
the adsorption time, the inoculum was removed and replaced by an appropriate
amount of post-infection medium (DMEM supplemented with 0.3% BSA, 20 mM
HEPES, and 1% penicillin-streptomycin) and cells were incubated for the indicated
times at 37 °C. Infectious particles in the supernatants of the cells were quantiﬁed
by plaque assay on MDCK cells.
Receptor Tyrosine kinase (RTK) proﬁling. For the initial analysis included in
Supplementary Figure 1a, a Proteome Proﬁler Human Phospho-RTK Array Kit
(R&D Systems) was used. Brieﬂy, A549 cells were seeded in 6-well plates and
serum-starved overnight. The following day, cells were infected with A/WSN/33 at
an MOI= 25 PFU/cell for 5 or 15 min, lysed and 300 μg of each lysate were used
according to manufacturer’s protocol. The membranes were read using a Lumi-
nescent Image Analyzer LAS-4000 Systems (FujiFilm) and signal intensities were
quantiﬁed by ImageJ.
SILAC labeling and preparation of cell extracts. Five biological replicates of the
phosphoproteomic experiment were performed using SILAC-labeled A549 cells.
For each replicate, two T150 ﬂasks of cells labeled with each of the following
conditions were used: L (light), where A549 cells were grown in normal DMEM; M
(medium), where A549 cells were grown in DMEM containing 4,4,5,5-D4 lysine
and 13C6 arginine; and H (heavy), where A549 cells were grown in DMEM con-
taining 13C6 15N2 lysine and 13C6 15N4 arginine. Incorporation of the different
isotopes was conﬁrmed by LC-MS/MS. Medium and heavy labeled cells were
infected with IAV (A/WSN/1933) at an MOI= 25 PFU/cell for 5 and 15 min,
respectively. Virus inoculum was prepared in infection PBS. As a mock-infection
control, an equivalent amount of allantoic ﬂuid from non-infected 10-day old
embryonated chicken eggs was diluted in infection PBS and added to unlabeled
cells (L). After the corresponding incubation time, the cells were directly lysed in
SDS-lysis buffer (4% (w/v) SDS, 100 mM Tris/HCl pH 8.2, 0.1 M DTT, Complete
(Roche) and Phos-Stop (Roche)) and the different cell extracts were pooled and
sonicated brieﬂy to reduce viscosity. In order to concentrate the samples, proteins
were precipitated using four volumes of −20 °C acetone and incubated overnight at
−20 °C. Following centrifugation (11,000 × g, 1 h, 4 °C), the precipitated protein
pellet was washed three times with −20 °C acetone, and then dried for 30 min.
Protein pellets were solubilized in a smaller volume of SDS-lysis buffer and the
protein concentration of the different replicates was determined using Qubit
ﬂuorometer (Invitrogen).
Trypsin digestion and phosphopeptide enrichment. Protein extracts were pro-
cessed using ﬁlter-aided sample preparation (FASP)58. Brieﬂy, 500 µg of protein
were diluted in urea buffer (8M urea in 100mM Tris/HCl pH 8.2) and loaded into
Microcon-30kDa Centrifugal Filter Units with Ultracel-30 membranes (Millipore).
The proteins were bound to the membrane by centrifugation and alkylated using a
50 mM iodoacetamide (IAA) solution in urea buffer. After washing three times with
urea buffer, the proteins were washed twice with 500mM NaCl and three times
using a 50 mM triethylammonium bicarbonate (TEAB) buffer pH 8.5. Overnight
on-ﬁlter digestion was performed with trypsin (Promega) at a ratio of 1:50 (w/w)
trypsin to protein, in a wet chamber at 37 °C. The tryptic peptides were eluted from
the ﬁlter by centrifugation and a second elution using 50mM TEAB buffer was
performed to increase the yield. A fraction of these peptides was collected for total
proteome analysis. Phosphopeptides were enriched by Ti4+-immobilized metal
afﬁnity chromatography (Ti-IMAC) and TiO2 afﬁnity chromatography using
magnetic microspheres (ReSyn Biosciences) and a magnetic separator (Thermo
Fisher Scientiﬁc). 1 mg of Ti-IMAC or TiO2 magnetic microspheres were washed
twice with 70% (v/v) ethanol and equilibrated once in 1% NH4OH and three times
in phosphopeptide loading buffer (1M glycolic acid in 80% (v/v) acetonitrile
(ACN), 5% (v/v) triﬂuoroacetic acid (TFA)). 500 µg of tryptic peptides were diluted
in loading buffer, added to 1mg of equilibrated magnetic microspheres and incu-
bated for 20min at RT with continuous rotation. After binding of the phospho-
peptides, the microspheres were washed once with loading buffer and unbound
peptides were removed by three washes with washing buffer (80% (v/v) ACN, 1%
(v/v) TFA). Phosphopeptides were eluted by incubation of the microspheres for
15 min in elution buffer (1% (v/v) NH4OH), acidiﬁed by addition of 10% (v/v)
formic acid (FA) and dried in a SpeedVac concentrator (Thermo Fisher Scientiﬁc).
Peptides were resuspended in 3% (v/v) ACN, 0.1% (v/v) TFA and desalted using
C18 ZipTips (Millipore). Filters were equilibrated once in a 60% (v/v) ACN, 0.1%
(v/v) TFA and subsequently twice in 0.1% (v/v) TFA solution. Peptides were bound
to the ﬁlters, washed three times with 0.1% (v/v) TFA and eluted in 60% (v/v) ACN,
0.1% (v/v) TFA. After drying them in a SpeedVac concentrator, peptides were
dissolved in 10 µl of LC-MS/MS solvent (3% (v/v) ACN, 0.1% (v/v) FA) prior to
LC-MS/MS analysis.
LC-MS/MS and initial data analysis. All data were acquired on an Orbitrap
Fusion Tribrid mass spectrometer (Thermo Scientiﬁc, San Jose, Ca), which was
connected to an Easy-nLC 1000 HPLC system (Thermo Scientiﬁc). 4 µl of the
peptide samples in 0.1% formic acid were loaded onto a frit column (inner dia-
meter 75 µm, length 15 cm) packed with reverse phase material (C18-AQ, particle
size 1.9 μm, pore size 120 Å, Dr. Maisch GmbH, Germany), and separated at a ﬂow
rate of 300 nl/per min. Solvent composition of buffer A was 0.1% formic acid in
water, and buffer B contained 0.1% formic acid in acetonitrile. For the phospho-
enriched samples, the following LC gradient was applied: 0 min: 2% buffer B,
110 min: 30% B, 120 min: 50% B, 122 min: 95% B. Survey scans were recorded in
the Orbitrap mass analyzer in the range of m/z 350–1500, with a resolution of
60,000 and a maximum injection time of 50 ms. Higher energy collisional dis-
sociation (HCD) spectra were acquired in the ion trap mass analyzer, using a
normalized collision energy of 28%. The precursor ion isolation width was set to
m/z 2.0, and a maximum injection time of 100 ms and an AGC target value of 3e4
were applied. Charge state screening was enabled, and charge states 2–7 were
included. The threshold for signal intensities was 1e4, and precursor masses already
selected for MS/MS acquisition were excluded for further selection during 30 s. For
total protein samples, the following LC gradient was applied: 0 min: 5% buffer B,
50 min: 25% B, 60 min: 32% B, 70 min: 97% B. Survey scans were recorded in the
range of m/z 300–1500, with a resolution of 120,000 and a maximum injection time
of 50 ms. HCD spectra were acquired in the ion trap, using a normalized collision
energy of 28%, an isolation window of m/z 1.6, a maximum injection time of
250 ms and an AGC target value of 1e2. The intensity threshold was 5e3 and the
dynamic exclusion duration was 25 s. A ﬁrst round of peptide identiﬁcation was
conducted in Mascot (www.matrixscience.com)59 and the phosphoenrichment
efﬁciency and the number of identiﬁcations for the different samples was evaluated
using Scaffold PTM 3.0. The mass spectrometry proteomics data have been
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deposited in the ProteomeXchange Consortium via the PRIDE60 partner repository
with the data set identiﬁer PXD009999.
MaxQuant analysis. Data acquired on the Orbitrap Fusion were analyzed with
MaxQuant v1.5.0.3023, searching a target-decoy database consisting of human
(88,708 forward Uniprot entries) and inﬂuenza A virus (A/WSN/33, 9 forward
Uniprot entries) sequences. As an additional control, a database containing chicken
sequences (43,340 forward Uniprot entries) was used for the identiﬁcation of IAV-
induced chicken proteins in our egg-grown stock. To identify contaminant proteins,
the internal contaminant database of MaxQuant was used. Search parameters were:
Cysteine carbamidomethylation as ﬁxed modiﬁcation, protein N-terminal acetyla-
tion and methionine oxidation and phosphorylation of serine, threonine and tyr-
osine as variable modiﬁcations; SILAC labeling (Arg10, Lys8, Arg6, Lys4) as heavy
labels; enzyme trypsin/P; two missed cleavages were allowed; and a minimum of
seven amino acids per identiﬁed peptide were required. The precursor ion mass
tolerance was set to 7 ppm, and the fragment mass tolerance was set to 20 p.p.m.
Peptide identiﬁcations were accepted until less than 1% of the reverse hits were
retained in the list. The protein false discovery rate (FDR) was set to 1%. For each
phosphopeptide in the data set, the median of the MaxQuant ratios for the different
replicates was calculated and the data from both TiO2 and Ti-IMAC based
approaches were combined for further analysis.
Pathway enrichment analysis. To identify the top enriched pathways, the dis-
tributions of annotated KEGG pathways22 among differentially phosphorylated
peptides at 5 and 15 min post infection (log2FC ≥ 0.5) were compared against the
background of all detected proteins in our MS analysis plus the ones previously
identiﬁed in a phosphoproteomic characterization of HIV infection61 (Supple-
mentary Figure 7). KEGG pathways for the whole population were retrieved (R
packages org.Hs.eg.db, v. 3.2.3, KEGG.db, v. 3.2.2) and a standard hypergeometric
test was performed followed by Bonferroni correction. Enrichment results are
presented in the context of the KEGG pathway topology using igraph (v.1.0.1).
Kinase prediction. The kinase prediction is derived from high stringency scores
calculated using the Group-based Prediction System 3.0 (GPS 3.0, http://gps.
biocuckoo.org/online.php)27–29, which ranks the likelihood that a particular kinase
or kinase family phosphorylates a given residue considering the amino acids sur-
rounding the phosphorylation site. All predictions for the experimentally detected
phosphorylation sites were ranked based on the difference between the site
threshold and the site prediction score (Supplementary Figure 7). In order to
determine the selection parameters we would use, given that more than one kinase
may be responsible for the phosphorylation of a given protein at a given position,
we ﬁrst worked on a subset of entries from Phospho.ELM (v.9.0, April 2015, http://
phospho.elm.eu.org/dataset.html). Brieﬂy, we downloaded all abstracts (n= 1690)
associated with all kinase-phosphosite pairs (rentrez 1.0.4) and selected those
reported in the context of viral infection (n= 160 unique sites on 51 unique
proteins, representing substrates of 12 major kinase groups, Supplementary Fig-
ure 2a). We subsequently ran GPS 3.0 on the full sequences of these proteins and
checked for conditions that allowed us to retrieve as many true positives per
phosphosite Pi from all predictions for Pi (Supplementary Figure 2b, c) using the
most stringent (2% false positive rate for serine/threonine kinases and 4% for
tyrosine kinases) prediction threshold. The top ﬁve predictions in terms of the
GPS-calculated score, which indicates the similarity of a detected phosphosite to a
phosphosite in the gold standard Phospho.ELM; or the derived parameter Delta,
deﬁned as the difference between the GPS-calculated score and the GPS-provided
cutoff per position, were found to include 70% of the true positives in this scenario
and was chosen as the cutoff for the kinase-phosphosite pairs that we report. Top
predicted kinases for the differentially phosphorylated sites at both 5 and 15 min
post infection (log2FC ≥ 0.5) were considered as IAV-responsive kinases. The
distribution of the top predicted kinases was then compared against the back-
ground of the total detected peptide population and enriched hits were identiﬁed.
To determine if the enrichment for a particular kinase is signiﬁcant, we performed
a 1000-fold random selection of peptides from all peptides detected in our assay,
where the number of peptides sampled per randomization is equal to the size of the
hyperphosphorylated peptides at 5 or 15 min post infection (log2FC > 0.5 wrt
mock). We subsequently compared the frequencies at which a top kinase is pre-
dicted for detected versus randomized conditions using Fisher’s exact test. For a
subset of the top predicted kinases (CDK1, CDK5, GRK2 and MAP2K1), sig-
niﬁcant enrichment cannot be established, given that their higher and more vari-
able scores (µCDK5,GRK2,CDK1,MAP2K1= 17.34+ 5.33, µother= 7.03+ 1.33) ensure
their inclusion in the top calls for any phosphosite for which these kinases are
predicted (Supplementary Figure 2c). Others, including PAK1 and CBK1, tend
towards enrichment (p value < 0.1 (Fisher's exact test)) and, consequently, we
cannot exclude their potential contribution to viral replication and included them
in our analysis. The computer code is available upon request.
Phosphorylation site consensus motifs. To ﬁnd motifs potentially linked to
phosphorylated sites associated with a kinase prediction, we ﬁrst grouped
sequences within +7 to +1 amino acids of the detected phosphorylation site (i.e.,
the phosphorylation site is at position 0); sequences can be included in more than
one group based on the assumption that different kinases may be responsible for
phosphorylation of a given protein at a given position. Sequences linked to each
predicted kinase group were submitted to WebLogo (http://weblogo.berkeley.edu/
logo.cgi) for motif detection (Supplementary Figure 7).
Inhibitor testing with WSN-Ren reporter virus. In order to quantitatively
measure the effect of the different chemicals on viral replication, we used a reporter
IAV derived from A/WSN/33, in which the coding sequence of the hemagglutinin
protein was replaced by that of Renilla luciferase to allow real-time determination
of viral replication62. The different kinase inhibitors were added to the A549 cells
together with the reporter virus at an MOI= 1 PFU/cell. After synchronizing
infection by allowing the virus to bind to target cells for 1 h at 4 °C, the inoculum
was removed and fresh culture medium containing the Renilla luciferase substrate
(EnduRen Live Cell Substrate, Promega) and the indicated concentrations of the
different inhibitors were added to the cells. The plates were transferred to 37 °C and
real-time luminescence measurements were performed at the different time-points
indicated using an EnVision Multilabel Reader (Perkin Elmer).
siRNA transfection and cell viability assay. A549, MRC5 or Wi38 cells were
reverse transfected with 30 nM siRNA (Qiagen) diluted in Opti-MEM (Life
Technologies) using the RNAiMAX reagent according to the manufacturer’s
protocol (Invitrogen). At 48 h post-transfection, cells were either infected or cell
viability was determined using the CellTiter-Glo assay (Promega). In addition, the
CellTiter-Glo kit was used to assess the effect of the different inhibitors on A549
cells in the absence of infection.
Western blot. Cell extracts were prepared using Laemmli buffer (62.5 mM Tris-
HCl pH 6.8, 25% glycerol, 2% SDS, 350 mM DTT, 0.01% Bromophenol Blue).
Samples were subjected to standard SDS-PAGE and proteins were transferred to
nitrocellulose membranes (Hybond ECL, GE Healthcare). Indicated primary
antibodies were used with ﬂuorescent secondary antibodies from Li-Cor and
images were acquired on a Odissey Fc imaging system.
Zn2+-Phos-tag SDS PAGE gels. For sample preparation, cells were lysed using a
pH neutral buffer (20 mM TrisHCl pH 8.1, 0.5% (v/v) NP-40, 200 mM NaCl,
cOmplete EDTA-free protease inhibitor cocktail (Roche) and PhosSTOP (Roche))
before Laemmli buffer was added. Gels were cast according to manufacturer’s
protocol (wako-chem) using Phos-tag™ AAL-107 (MW: 595, Wako Cat. No. 304-
93525). Samples were run on the Zn2+-Phos-tag SDS PAGE gels for 4 h at 60 V
and were blotted over night at 4 °C onto nitrocellulose membranes (Hybond ECL,
GE healthcare). Staining and analysis were done as described for standard SDS-
PAGE. For the blots shown in Fig. 3d, e, the uncropped versions of the blots are
provided in Supplementary Figure 8.
GRK2 translocation assay. Hep-2 cells were grown on glass coverslips in 24-well
plates and transfected with HA-GRK2 (a kind gift from Dr. U. Quitterer, ETH
Zurich, Switzerland) and pcDNA6A-myc-EGFR (a kind gift from Mien-Chie Hung
(Addgene plasmid # 4266563)) using ViaFect (Promega) as transfection reagent.
After infection with A/WSN/1933 with an MOI= 100 PFU/cell or stimulation with
hrEGF (100 ng/ml), cells were processed for immunoﬂuorescence as described
below.
Immunoﬂuorescence staining and confocal microscopy. For immuno-
ﬂuorescence staining, A549, Hep-2 or MDCK cells were grown on glass coverslips
in 24-well plates. In the case of HAE cultures, cells were ﬁxed and stained directly
on the membrane. After infection cells were ﬁxed with 3% paraformaldehyde
(PFA) and permeabilized using immunoﬂuorescence (IF) buffer (PBS supple-
mented with 50 mM NH4Cl, 0.1% saponin, and 2% BSA). After 30 min in IF buffer,
the cells were incubated overnight at 4 °C with the corresponding primary anti-
bodies diluted in IF buffer. Cells were washed three times with IF buffer and
incubated with the secondary antibodies diluted in DAPI-containing IF buffer for
1 h at RT. Alexa Fluor-conjugated donkey anti-mouse/rabbit antibodies (catalog
no. A-21202, A-21206, A10036, and A10040; Life Technologies) were used as
secondary antibodies. Cells were washed three times with IF buffer, before the
coverslips or membranes were dipped in deionized water and inversely mounted
onto glass microscope slides using ProLong Gold Antifade Mountant (Thermo
Fisher Scientiﬁc). All microscopy images were acquired with a confocal laser
scanning microscope (Leica SP5). The quantiﬁcation of the nuclear NP signal
was performed using an automated macro in ImageJ. Statistical analysis of the
different images was done using PRISM software. For the endosomal co-
localization analysis, Imaris software was used with standard co-localization set-
tings and masks.
Virus-like particle (BlaM1 VLP) production and infection. A/WSN/33-based
VLPs harboring β-lactamase-M1 (BlaM1) fusion proteins were produced essen-
tially as described by Tscherne & Garcìa-Sastre42. Brieﬂy, HEK 293 T cells seeded
onto poly-L-lysine-coated (Sigma-Aldrich) 6-well plates were transfected in Opti-
MEM (Life Technologies) with 2 μg BlaM1, 500 ng pCAGGS-WSN-HA, 500 ng
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pCAGGS-WSN-NA per well using ViaFect (Promega) as the transfection reagent
(3 µl ViaFect/µg DNA). Medium was exchanged 6 h post-transfection with Opti-
MEM (Life Technologies) containing 1% penicillin-streptomycin. VLPs were col-
lected 72 h after transfection and treated with 5 μg/mL TPCK-trypsin (Sigma-
Aldrich) for efﬁcient HA cleavage. Trypsin was inactivated with 10 μg/mL trypsin
inhibitor from Glycine max (Sigma-Aldrich). Prior to infection, MDCK cells were
treated with the indicated concentrations of the GRK2 inhibitor for 1 h. For
infection of MDCK cells in 24-well plates, 200 μl BlaM1 VLPs were added to the
cells in the presence of the compound and incubated for 4 h at 37 °C. Cells were
harvested by trypsinization and incubated with the ﬂorigenic substrate CCF2-AM
(ThermoFisher Scientiﬁc). Cells were analyzed on a FACSVerse System (BD) and
dead cells excluded by a live/dead staining (LIVE/DEAD Fixable Near-IR Dead Cell
Stain Kit, ThermoFisher Scientiﬁc).
Mouse experiments. 9 week old C57BL/6J mice (Charles River, France) were
injected i.p. with 5 mg/kg paroxetine in 5% DMSO in PBS or 5% DMSO in PBS
(solvent) 24 h prior to infection. Mice were infected after ketamine (100 mg/kg)/
xylazine (5 mg/kg) anaesthesia (i.p.) with 10 PFU of A/Netherlands/602/2009
(pdmH1N1) (kindly provided by Dr. F. Krammer, Icahn School of Medicine at
Mount Sinai, New York) or inoculated with PBS via the intranasal route. Parox-
etine or solvent treatment was repeated on d0, d1 and d2 pi. The ﬁrst group of mice
was sacriﬁced on d2 and d4 pi by controlled CO2 exposure and lungs and snout
were removed aseptically. Organs were homogenized in 1 ml sterile PBS using
sterile 1/4” steel or ceramic beads in a 2 ml screw cap tube using a BeadBlaster
24 Position Homogenizer (Benchmark Scientiﬁc) at 6 m/s for two times 30 s with a
30 s break on ice. Homogenates were precipitated at 10,000 g for 10 min and clear
supernatants were analyzed for infectious virus particles using standard plaque
assay on MDCK. The second group of mice was monitored daily for weight loss
and survival up to d7 when all infected mice reached humane endpoints. All animal
procedures were in accordance with federal regulations (Schweizer Bundesamt für
Veterenärwesen BVET), controlled by institutional (Direction de l’expérimentation
animale d’universite de Geneve) and cantonal authorities (Commission cantonale
de Geneve pour les expériences sur les animaux) and approved under license no
GE/159/17.
Data Availability
The mass spectrometry proteomics data have been deposited in the ProteomeXchange
Consortium via the PRIDE60 partner repository [http://www.ebi.ac.uk/pride] with the
data set identiﬁer PXD009999. The authors declare that all other data supporting the
ﬁndings of this study are available within the article and its Supplementary Information
ﬁles, or are available from the authors upon request.
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